Galapagos/$GLPG
13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1Y5YMAX
About Galapagos
Galapagos NV is a fully integrated biotechnology company with operations in Europe and the United States, dedicated to developing medicines focusing on oncology and immunology. The group focuses on unmet medical needs, it synergizes compelling science, technology, and collaborative approaches to create a deep pipeline of medicines. Its clinical pipeline includes: GLPG5101, a CD19 CAR-T product candidate decentralized manufactured, currently in Phase 1/2 in rrNHL; GLPG5301, a BCMA CAR-T product candidate decentralized manufactured, currently in Phase 1 in rrMM; and GLPG3667, a TYK2 inhibitor currently in Phase 2 clinical trial in DM and SLE. It derives maximum revenue from the United States of America.
Ticker
$GLPG
Sector
Primary listing
Industry
Biotechnology
Headquarters
Employees
704
ISIN
US36315X1019
Website
Galapagos Metrics
BasicAdvanced
$1.8B
-
-$3.01
-0.06
-
Price and volume
Market cap
$1.8B
Beta
-0.06
52-week high
$29.48
52-week low
$22.59
Average daily volume
382K
Financial strength
Current ratio
7.945
Quick ratio
7.736
Long term debt to equity
0.283
Total debt to equity
0.395
Interest coverage (TTM)
-217.59%
Profitability
EBITDA (TTM)
-322.783
Gross margin (TTM)
45.46%
Net profit margin (TTM)
-58.83%
Operating margin (TTM)
-108.49%
Effective tax rate (TTM)
1.67%
Revenue per employee (TTM)
$479,000
Management effectiveness
Return on assets (TTM)
-4.66%
Return on equity (TTM)
-6.36%
Valuation
Price to revenue (TTM)
5.423
Price to book
0.57
Price to tangible book (TTM)
0.62
Price to free cash flow (TTM)
-4.926
Free cash flow yield (TTM)
-20.30%
Free cash flow per share (TTM)
-562.58%
Growth
Revenue change (TTM)
18.31%
Earnings per share change (TTM)
-160.73%
3-year revenue growth (CAGR)
-17.18%
10-year revenue growth (CAGR)
12.66%
3-year earnings per share growth (CAGR)
10.36%
10-year earnings per share growth (CAGR)
24.05%
Bulls say / Bears say
Galapagos' strategic decision to spin off its innovative medicines unit by mid-2025 aims to provide clearer business prospects for investors, potentially enhancing shareholder value. (reuters.com)
Gilead Sciences' recent acquisition of a 25.35% stake in Galapagos underscores confidence in the company's future, potentially leading to collaborative synergies. (marketbeat.com)
Galapagos reported a 20.1% increase in revenue to €74.98 million for the quarter ended March 31, 2025, indicating positive sales momentum. (tradingview.com)
The planned spin-off will result in approximately 300 job reductions, about 40% of the workforce, which may lead to operational challenges. (reuters.com)
Galapagos reported a quarterly adjusted loss of €2.33 per share for Q1 2025, significantly missing analyst expectations of a €0.21 loss, raising concerns about financial stability. (tradingview.com)
Analysts have set a consensus 12-month price target of $25.33 for Galapagos, suggesting limited upside potential from current levels. (defenseworld.net)
Data summarised monthly by Lightyear AI. Last updated on 6 Jun 2025.
Galapagos News
AllArticlesVideos
Galapagos Appoints Aaron Cox as Chief Financial Officer
GlobeNewsWire·4 days ago
Galapagos Presented New Data at ICML 2025 From Cohort 3 of ATALANTA-1 in Relapsed/Refractory Indolent NHL Patients, Demonstrating High Complete Response and MRD Negativity Rates With CAR-T Candidate GLPG5101
GlobeNewsWire·1 week ago
Galapagos to Present New ATALANTA-1 CAR-T Data at EHA 2025, Highlighting Low Toxicity and Rapid, Decentralized Delivery of Fresh, Early-Memory-Enriched GLPG5101 in R/R NHL
GlobeNewsWire·2 weeks ago
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.
Capital at risk
Upcoming events
No upcoming events
FAQs
What’s the current market cap for Galapagos stock?
Galapagos (GLPG) has a market cap of $1.8B as of June 27, 2025.
What is the P/E ratio for Galapagos stock?
The price to earnings (P/E) ratio for Galapagos (GLPG) stock is 0 as of June 27, 2025.
Does Galapagos stock pay dividends?
No, Galapagos (GLPG) stock does not pay dividends to its shareholders as of June 27, 2025.
When is the next Galapagos dividend payment date?
Galapagos (GLPG) stock does not pay dividends to its shareholders.
What is the beta indicator for Galapagos?
Galapagos (GLPG) has a beta rating of -0.06. This means that it has an inverse relation to market volatility.